Armand A. Della Monica, P.C.

Kirkland & Ellis advised private equity and credit firm ABRY Partners in the sale of a majority stake in Blue Mantis to Recognize, a private equity firm focused on investing in technology services businesses with a thematic and operationally-oriented strategy. Blue Mantis is a premier IT services provider with deep expertise in managed services, cybersecurity and cloud solutions. ABRY Partners, which has backed Blue Mantis since 2020, will continue as a minority investor in the company. The transaction was announced September 9, 2024. Read the transactions press release The Kirkland team was led by corporate partner Amanda Border and tax partner Vincent Thorn, with support from corporate partner Armand Della Monica.

Sep 10

1 min

Kirkland & Ellis advised Nordic Capital-backed Orchid Orthopedic Solutions on a definitive agreement to merge with Tecomet. Orchid provides solutions for procedures in major MedTech markets in the U.S. and Europe. Tecomet is a global leader in the design, development and manufacture of MedTech and Aerospace & Defense products. The combined company will offer an enhanced portfolio of MedTech solutions with a broader, more resilient manufacturing footprint and increased capacity to invest in advanced manufacturing, automation and capacity expansion aligned with customer demand. The combined company will have the joint support of both Charlesbank Capital Partners and Nordic Capital, who have been the majority owners of Tecomet and Orchid since 2017 and 2019, respectively. Read the transaction press release The Kirkland team included corporate lawyers Duncan Enista, Costa Skarvelis, Armand Della Monica, Jonas Goransson and Adi Sharma; debt finance lawyers Jason Kanner, Ashley Martin, Daniel Clayman and Danielle Gagné; and tax lawyers Vivek Ratnam, Mike Beinus and Joseph Riddle.

Jan 22

1 min

Kirkland & Ellis advised Nautic Partners portfolio company CarepathRx Health System Solutions (CHSS), a CarepathRx company, on its new strategic partnership and investment by Evernorth Health Services, a subsidiary of The Cigna Group (NYSE: CI). The strategic partnership brings together Evernorth's diverse specialty and care expertise with CHSS' robust pharmacy and infusion management capabilities, technology solutions and health system relationships to improve, expand and accelerate pharmacy care delivery for the growing number of patients with chronic and complex care needs. Read CarepathRx’s press release The Kirkland team was led by corporate partners Armand Della Monica and Duncan Enista and associate William Lay; and debt finance partner John Ilardo.

Jun 1

1 min

Kirkland & Ellis advised Nautic Partners on a growth investment in KabaFusion, a nationally recognized leader in home and alternative site infusion. KabaFusion’s clinician-led management team remains significant investors and will continue to lead the company, while Novo Holdings exited its successful investment in the company. Read the transaction press release The Kirkland team included corporate lawyers Duncan Enista, Armand Della Monica and Annie Cataldo; tax lawyer Devin Heckman; and executive compensation lawyers Jabir Yusoff and Jenny Cha.

Feb 3

1 min

Kirkland & Ellis is advising global investment firm Carlyle (NASDAQ: CG) on the $3.8 billion acquisition of global medtech company Baxter International Inc.’s (NYSE:BAX) kidney care segment, which will be named Vantive. The transaction was announced on August 13, 2024. Under the terms of the definitive agreement, subject to certain closing adjustments, Baxter will receive approximately $3.5 billion in cash with net after-tax proceeds currently estimated to be approximately $3 billion. Carlyle’s investment in Vantive is being made in partnership with Atmas Health, a collaboration among three industry executives founded in September 2022 to focus on acquiring and building a market-leading healthcare business. Baxter announced the intention to create a standalone kidney care company in January 2023 as part of its broader strategic realignment designed to enhance future performance and create value for all stakeholders. In March 2024, the company announced that it was in discussions to explore a potential sale of the segment. The transaction is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Read the transaction press release The Kirkland team is being led by corporate partners Armand Della Monica, Laura Steinke and Nils Remole; debt finance partners Jason Kanner and Justin Greer; tax partners Dean Shulman and Adam Kool; and technology & IP transactions partners Matt Lovell and Kevin Jacobsen.

Aug 13

1 min